

Dr. Kate Baker is a medical oncologist and Medical Director of Value-Based Care at Tennessee Oncology.
Podcasts
Tumor Board # 87Oct 27, 2026Diagnosis & Management of Advanced HER2-Negative Upper GI Cancers

Five years ago, first-line treatment for advanced HER2-negative gastroesophageal cancer meant chemotherapy; today claudin 18.2, PD-L1, and mismatch repair status shape the plan, often for a patient who cannot afford to wait for the results. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews medical oncologists Dr. Ronan Hsieh and Dr. Dani Castillo about the diagnosis and management of advanced HER2-negative upper GI cancers. They discuss the biomarker workup at diagnosis, next-generation sequencing and liquid biopsy, when to biopsy metastatic sites, and why both guests start chemotherapy before every result is available.
Tumor Board # 86Oct 20, 2026Optimizing Treatment for Advanced HER2-Positive Upper GI Cancers

When a gastroesophageal tumor is positive for HER2, PD-L1, and claudin 18.2, which target should you treat first and how do you decide? On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews Dr. Geoffrey Buckle, a GI medical oncologist at UCSF, and Dr. Ronan Hsieh, a GI oncologist at Swedish Cancer Institute in Seattle, for a breakdown of therapy selection and management in advanced HER2-positive upper GI cancers. They start with a detailed case, covering biomarker workup, how to choose a first-line regimen without head-to-head data, and how to manage nutrition and palliative radiation when a patient presents with dysphagia and weight loss.
Tumor Board # 85Oct 13, 2026Perioperative Management in Upper GI Cancers

How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope in Duarte, California, and Dr. Alexandra Gangi, a gastrointestinal surgical oncologist at Cedars-Sinai in Los Angeles, about everything that happens between a new diagnosis and a resection in localized esophageal, gastroesophageal junction and gastric cancer. They cover diagnostic workup, Siewert classification, staging laparoscopy, histology, biomarker testing, surgical candidacy, and the challenges of nutrition and prehabilitation.
Tumor Board # 77Aug 18, 2026AI's Impact on Oncology Practice

Where is AI already making oncology practice more efficient, and where does human expertise remain irreplaceable? In this episode of BackTable Tumor Board, medical oncologists Dr. Kate Baker and clinical data expert Larry Bilbrey discuss how AI is improving oncology workflow, such as scribing and information retrieval, but is far from replacing clinicians, especially for hands-on care.
Tumor Board # 73Jul 21, 2026Comprehensive Care in Breast Cancer Survivorship

When breast cancer treatment ends, recurrence surveillance can easily overshadow the symptoms and concerns that continue to affect daily life. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Lindsay Peterson discuss how effective survivorship care can address recurrence anxiety, endocrine therapy toxicities, bone health, sexual health, and the broader emotional and practical needs of patients after treatment.
Industry # 102Jun 16, 2026Community Oncology: Keeping Up with Evolving Treatments in Early Career

The transition between residency or fellowship to clinical practice can be a big jump, especially when it comes to keeping up with new data and independently making decisions with patients. In this episode of BackTable Industry, Anish Parikh hosts medical oncologist Dr. Kate Baker shares her experience managing a broad range of patients, from solid tumors to benign and malignant hematology.
Tumor Board # 52Mar 24, 2026Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer

Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings.
Tumor Board # 47Feb 10, 2026NSCLC Treatment: Bispecific Antibodies & EGFR Mutations

Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do they work, where do they fit in clinical practice, and what should oncologists be thinking about next? In this episode of Back Table Tumor Board, Dr. Kate Baker and Dr. Wade Iams from Tennessee Oncology answer these questions and more.